Skip to main content
Erschienen in: Journal of Cancer Education 4/2012

01.12.2012

Breast Cancer Treatment of Women with Schizophrenia and Bipolar Disorder from Philadelphia, PA: Lessons Learned and Suggestions for Improvement

verfasst von: Marion Cole, Aruna Padmanabhan

Erschienen in: Journal of Cancer Education | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Treating cancer in patients with concurrent severe mental illness is complex and challenging for patients, families, and health care providers. Two such illnesses include schizophrenia and bipolar disorder. In this review, cases of women with breast cancer and severe mental illness from Philadelphia, PA illustrate the obstacles these women face in maintaining adequate cancer care. Barriers to receiving cancer treatment include understanding their disease, continuing medications and appointments, and experiencing complications of their psychiatric disorders. Learning from these cases is critical for health care providers and allows for innovation in treating and educating this difficult population. Increasing patient visit time, using social support services, and psychiatrist and psychiatrist-liaisons are necessary to improve care. In addition, family or caregivers should be included in discussions when possible. These techniques will assist in educating patients, improve insight into their disease and treatment, and allow them to benefit from cancer therapy.
Literatur
1.
Zurück zum Zitat Howard LM, Barley EA, Davies E, Rigg A, Lempp H, Rose D, Taylor D, Thornicroft G (2010) Cancer diagnosis in people with severe mental illness: practical and ethical issues. Lancet 11:797–804CrossRef Howard LM, Barley EA, Davies E, Rigg A, Lempp H, Rose D, Taylor D, Thornicroft G (2010) Cancer diagnosis in people with severe mental illness: practical and ethical issues. Lancet 11:797–804CrossRef
2.
Zurück zum Zitat Moini B, Levenson JL (2009) A forgotten diagnosis: simple schizophrenia in a patient with breast cancer. Psychosomatics 50(1):87–89PubMedCrossRef Moini B, Levenson JL (2009) A forgotten diagnosis: simple schizophrenia in a patient with breast cancer. Psychosomatics 50(1):87–89PubMedCrossRef
3.
Zurück zum Zitat BarChana M, Levav I, Lipshitz I, Pugachova I, Kohn R, Weizman A, Grinshpoon A (2008) Enhanced cancer risk among patients with bipolar disorder. J Affect Disord 108:43–48PubMedCrossRef BarChana M, Levav I, Lipshitz I, Pugachova I, Kohn R, Weizman A, Grinshpoon A (2008) Enhanced cancer risk among patients with bipolar disorder. J Affect Disord 108:43–48PubMedCrossRef
4.
Zurück zum Zitat Hodgson R, Wildgust HJ, Bushe CJ (2010) Cancer and schizophrenia: is there a paradox? J Psychopharmacol 24(11 Supplement 4):51–60PubMedCrossRef Hodgson R, Wildgust HJ, Bushe CJ (2010) Cancer and schizophrenia: is there a paradox? J Psychopharmacol 24(11 Supplement 4):51–60PubMedCrossRef
5.
Zurück zum Zitat Inagaki T, Yasukawa R, Okazaki S, Yasuda H, Kawamukai T, Utani E, Hayashida M, Mizuno S, Miyaoka T, Shinno H, Horiguchi J (2006) Factors disturbing treatment for cancer in patients with schizophrenia. Psychiatry Clin Neurosci 60:327–331PubMedCrossRef Inagaki T, Yasukawa R, Okazaki S, Yasuda H, Kawamukai T, Utani E, Hayashida M, Mizuno S, Miyaoka T, Shinno H, Horiguchi J (2006) Factors disturbing treatment for cancer in patients with schizophrenia. Psychiatry Clin Neurosci 60:327–331PubMedCrossRef
6.
Zurück zum Zitat Fair AM, Wujcik D, Lin JS, Zhen W, Egan KM, Grau AM, Champion VL, Wallston KA (2010) Psychosocial determinants of mammography follow-up after receipt of abnormal mammography results in medically underserved women. J Health Care Poor Underserved 21(1 Suppl):71–94PubMed Fair AM, Wujcik D, Lin JS, Zhen W, Egan KM, Grau AM, Champion VL, Wallston KA (2010) Psychosocial determinants of mammography follow-up after receipt of abnormal mammography results in medically underserved women. J Health Care Poor Underserved 21(1 Suppl):71–94PubMed
7.
Zurück zum Zitat Blanchard J, Ogle K, Thomas O, Lung D, Asplin B, Lurie N (2008) Access to appointments based on insurance status in Washington, D.C. J Health Care Poor Underserved 19(3):687–696PubMedCrossRef Blanchard J, Ogle K, Thomas O, Lung D, Asplin B, Lurie N (2008) Access to appointments based on insurance status in Washington, D.C. J Health Care Poor Underserved 19(3):687–696PubMedCrossRef
8.
Zurück zum Zitat McWilliams S, Hill S, Mannion N, Fetherston A, Kinsella A, O’Callaghan E (2012) Schizophrenia: a five-year follow-up of patient outcome following psycho-education for caregivers. Eur Psychiatry 27(1):56–61PubMedCrossRef McWilliams S, Hill S, Mannion N, Fetherston A, Kinsella A, O’Callaghan E (2012) Schizophrenia: a five-year follow-up of patient outcome following psycho-education for caregivers. Eur Psychiatry 27(1):56–61PubMedCrossRef
9.
Zurück zum Zitat Han WT, Collie K, Koopman C, Azarow J, Classen C, Morrow GR, Michel B, Brennan-O’Neill E, Spiegel D (2005) Breast cancer and problems with medical interactions: relationships with traumatic stress, emotional self-efficacy, and social support. Psychooncology 14(4):318–330PubMedCrossRef Han WT, Collie K, Koopman C, Azarow J, Classen C, Morrow GR, Michel B, Brennan-O’Neill E, Spiegel D (2005) Breast cancer and problems with medical interactions: relationships with traumatic stress, emotional self-efficacy, and social support. Psychooncology 14(4):318–330PubMedCrossRef
Metadaten
Titel
Breast Cancer Treatment of Women with Schizophrenia and Bipolar Disorder from Philadelphia, PA: Lessons Learned and Suggestions for Improvement
verfasst von
Marion Cole
Aruna Padmanabhan
Publikationsdatum
01.12.2012
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Education / Ausgabe 4/2012
Print ISSN: 0885-8195
Elektronische ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-012-0391-7

Weitere Artikel der Ausgabe 4/2012

Journal of Cancer Education 4/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.